Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Nordic firms have outperformed those from the rest of Europe over the past decade. In all four countries, listed ...
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with ...
Verywell Health on MSN2d
Another Study Links Ozempic to a Rare Eye Condition That Can Cause Vision LossA new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback